Bionano Genomics Announces Issuance of Two U.S. Patents for Novel Methods that Expand Patent Protection for Uses of Nanochannel Arrays in Genome Analysis
The ‘999 patent, titled “Photocleavage method and apparatus to clean fluidic devices,” claims a novel apparatus and method for using a light source to minimize aggregation of biopolymers in or around a nanochannel. This technology is used by Bionano to enable multiple cycles of DNA loading, imaging, clearing and reloading, making it important to the performance of Bionano’s nanochannel arrays. This patent family also includes issued patents in
The ‘713 patent, titled “Integrated analysis devices analysis techniques,” expands upon the company’s existing patent protection for its optical genome mapping (OGM) technology. The patent claims methods of identifying genomic sequences or structural genomic variants (SV) by linearizing target DNA molecules through a series of nanochannels within a nanochannel array and detecting of specific signals that correlate with a property of the target DNAs.
Bionano’s intellectual property portfolio includes multiple patents covering its core technology issued both in the US and internationally. Additionally, Bionano’s portfolio includes patents directed to methods of fabricating nanochannel devices, as well as other technologies for sample processing and analysis related workflows.
“Bionano continues to innovate, adding proprietary capabilities to our OGM systems,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. “The patents issued last week provide further protection of our intellectual property and is expected to strengthen our global patent portfolio. We continue to strive to create powerful, scalable tools that can provide new insight into structural variants in key areas of clinical research, including cancer and constitutional genetic disease.”
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits and improvements resulting from the methods and apparatus described in these patents, and the ability of the tools that we may develop to provide new insight into structural variants in key areas of clinical research, including cancer and constitutional genetic disease. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements in existing technologies; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
+1 (858) 888-7610
+1 (858) 366-3243
Source: Bionano Genomics